Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

It's not fully appreciated how much of an impact sickle cell disease can have on a person's mental health, writes columnist.

and hemoglobinopathies, including sickle cell disease and glucose-6-phosphate dehydrogenase deficiency. Lastly, a practical approach to the diagnosis of chronic anemia is presented. Anemia is ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.

13 In this way, it may resemble the hemoglobinopathies such as sickle-cell disease and hemoglobin C, which are also known to have relatively limited geographic distribution. The retrospective ...